{
    "root": "aeee81bb-b8cf-4b57-bc85-813fcc74c79d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "fenofibrate",
    "value": "20250131",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "Fenofibrate tablets are peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications": "Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily ( 2.2 ). Severe hypertriglyceridemia: Initial dose of 48 mg to 145 mg once daily. Maximum dose is 145 mg ( 2.3 ). Renally impaired patients: Initial dose of 48 mg once daily ( 2.4 ). Geriatric patients: Select the dose on the basis of renal function ( 2.5 ). May be taken without regard to meals ( 2.1 ).",
    "warningsAndPrecautions": "Fenofibrate tablets, USP 145 mg tablets are white, oval shaped, biconvex, film coated tablets debossed with \"159\" on one side and plain on other side.\n                  \n                     NDC 71335-2413-1: 30 Tablets in a BOTTLE\n                     NDC 71335-2413-2: 90 Tablets in a BOTTLE\n                     NDC 71335-2413-3: 28 Tablets in a BOTTLE\n                  \n                  Store at 20째 to 25째C (68째 to 77째F) [see USP Controlled Room Temperature]. Keep out of reach of children. Protect from moisture.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Fenofibrate tablets are contraindicated in:\n                  \n                     patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].\n                     patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].\n                     patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].\n                     nursing mothers [see Use in Specific Populations (8.2)].\n                     patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)]."
}